Variation in the neuropathological assessment of autopsy brains from patients clinically diagnoses as Alzheimer's disease (AD) has hampered clinical-pathological correlative studies and pooling of data from multiple centers. To overcome this problem, the Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a neuropathology data and to achieve quality assurance. CERAD neuropathologists have agreed to participate in the standardization studies proposed in this application.
The specific aims of the Neuropathology Task Force are: (1) To apply a brief, reliable, and standardized neuropathological protocol for the examination of autopsy brains from patients clinically diagnoses as AD and to achieve quality assurance for this assessment. (2) To analyze the relationship between neuropathological changes in the brain and specific CERAD clinical, neuropsychological, and neuro-imaging findings and, when possible, to analyze the nature and neuroanatomical distribution of specific AD findings in patients with mild disease. (3) To assess the types and frequency of other dementing disorders coexisting with AD or occurring alone. (4) To investigate overlapping neuropathological findings of Parkinson's disease and cerebrovascular disease in neuropathologically-confirmed AD cases and to correlate these findings with specific CERAD clinical manifestations. (5) To review nd pool information on unusual neuropathological cases from patients diagnosed clinically as having Alzheimer's disease. (6) To develop an archival computerized imaging system for capture, storing and displaying selected neuropathological findings in a manner appropriate for documentation, research, and educational purposes that can be utilized by CERAD and non-CERAD investigators alike. The clinical-pathological correlative aims described above will be a cooperative effort involving the Clinical, Neuropsychological, Neuroimaging, and the Methodology and Data Management Task Forces. In addition to these goals, we plan to undertake a pilot study to determine the feasibility of establishing an archival imaging system during the third year of this program.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AG006790-04
Application #
3814083
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Fillenbaum, Gerda G; Burchett, Bruce M; Unverzagt, Frederick W et al. (2011) Norms for CERAD constructional praxis recall. Clin Neuropsychol 25:1345-58
Fillenbaum, Gerda G; van Belle, Gerald; Morris, John C et al. (2008) Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement 4:96-109
Klatte, Emily T; Scharre, Douglas W; Nagaraja, Haikady N et al. (2003) Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 17:113-6
Taylor Jr, Donald H; Fillenbaum, Gerda G; Ezell, Michael E (2002) The accuracy of medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol 55:929-37
Fillenbaum, G; Heyman, A; Peterson, B L et al. (2001) Use and cost of outpatient visits of AD patients: CERAD XXII. Neurology 56:1706-11
Fillenbaum, G; Heyman, A; Peterson, B L et al. (2001) Use and cost of hospitalization of patients with AD by stage and living arrangement: CERAD XXI. Neurology 56:201-6
Fillenbaum, G; Heyman, A; Peterson, B et al. (2000) Frequency and duration of hospitalization of patients with AD based on Medicare data: CERAD XX. Neurology 54:740-3
Clark, C M; Sheppard, L; Fillenbaum, G G et al. (1999) Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 56:857-62
Heyman, A; Fillenbaum, G G; Gearing, M et al. (1999) Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX. Neurology 52:1839-44
Koss, E; Peterson, B; Fillenbaum, G G (1999) Determinants of attrition in a natural history study of Alzheimer disease. Alzheimer Dis Assoc Disord 13:209-15

Showing the most recent 10 out of 66 publications